Models

EntreMed's Aurora Kinase Inhibitor Induces Tumor Regression in Preclinical Models

ROCKVILLE, Md., June 01, 2007 /PRNewswire-FirstCall/ --EntreMed, Inc. , a clinical-stage pharmaceutical company developingtherapeutics for the treatment of cancer and inflammatory diseases,announced the presentation of preclinical results for its Aurorakinase - angiogenesis inhibitor, ENMD-981693. The data werepresented during oral and poster presentations by EntreMedscientists at the 2n...

VGX Pharmaceuticals' Novel HIV and Pandemic Influenza DNA Vaccine Candidates Trigger Robust Immune Responses and Protection in Pre-Clinical Models

MALAGA, Spain--(BUSINESS WIRE)--May 23, 2007 - VGX Pharmaceuticals'novel pandemic influenza vaccine candidates triggered protectiveimmune responses in pre-clinical challenge studies, according todata presented for the first time today at the Third InternationalConference on DNA Vaccines in Malaga, Spain. VGX scientists created four synthetic consensus DNA vaccines toprotect against a leth...

Data Presented at AACR Meeting Show Peregrine's Bavituximab Equivalent Can Generate Curative Immune Responses as Part of a Vaccine-Like Regimen in Preclinical Models of Aggressive Brain Cancer

--Immunization with a Bavituximab Equivalent and Irradiated TumorCells Increased Long-Term Survival to 57% From 0% in Controls in aPreclinical Model of Brain Cancer-- LOS ANGELES and TUSTIN, Calif., April 18, 2007/PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. , aclinical stage biopharmaceutical company developing targetedmonoclonal antibodies for the treatment of cancer and hep...

Medarex Presents Preclinical Data Demonstrating Potent Anti-Tumor Activity of Anti-CD19 and Anti-CD70 Antibody-Drug Conjugates in Cancer Animal Models

- Data presentations at American Association for Cancer Researchannual meeting - PRINCETON, N.J., April 17, 2007 /PRNewswire-FirstCall/ --Medarex, Inc. today presented preclinical data demonstrating potentanti- tumor activity from two separate studies exploring theefficacy and safety in animal models of anti-CD19 and anti-CD70antibody-drug conjugates. CD19 and CD70 are both attractive tar...

EntreMed Presents Multi-Mechanism Antitumor Data for ENMD-1420 in Preclinical Models

Tumor Inhibition Demonstrated in Lung and Colorectal Cancers ROCKVILLE, Md., April 16, 2007 /PRNewswire-FirstCall/ --EntreMed, Inc. , a clinical-stage pharmaceutical company developingtherapeutics for the treatment of cancer and inflammatory diseases,announced the presentation of results for its preclinical tubulininhibitor compounds. The data were presented by EntreMed scientistsat the A...

Data Presented at AACR Meeting Shows Peregrine's Selective Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical Cancer Models

- Peregrine's Selective Anti-VEGF Antibodies Inhibited Tumor Growth By 90% In a Preclinical Cancer Model - - Peregrine's Antibodies that Selectively Inhibit VEGF Receptor2 Could - These Results Along with Data Presented on a Fully HumanAntibody Support Advancing Peregrine's...